Tolero Pharmaceuticals Finds $14.2M
Salt Lake City, Utah-based Tolero Pharmaceuticals, a biopharmaceuticals firm which is targeting oncology and hematologic disease, has raised $14.2M in a Series B funding round. The company said the round was led by Fred Alger Management Inc., and also included other institutional and individual investors. Tolero's lead program is aimed at treating acute myeloid leukemia (AML). The company said the funds go towards further development and commercialization of the product. Tolero Pharmaceuticals is led by Dr. David Bearss.
posted on Friday, August 8, 2014 (Link to more information)
Related companies:
Tolero Pharmaceuticals, Inc.
Related stories:
> Tolero Pharmaceuticals Bumps Series B To $22.4M
> Prolexys Pharmaceuticals Raises $20M
> N30 Pharmaceuticals Names New CEO
> ZARS In Agreement With Endo Pharmaceuticals
> Recursion Pharmaceuticals Raises $60M
Techrockies.com Home